Atlas Trials

A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL

Clinical trial NCT06022224 · TERMINATED

Trial details

NCT number
NCT06022224
Sponsor
ImmunityBio, Inc.
Status
TERMINATED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
COVID-19
Start date
2020-12-09
Primary completion
2022-06-23
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.